Sign in Subscribe
Class action lawsuits

Sarepta Therapeutics, Inc. Faces Class Action Suit Over Alleged Misleading Investors About ELEVIDYS Drug Safety

Strategic Insights

— 1 min read

Investors who purchased or acquired Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 22, 2023, and June 24, 2025, may be eligible to participate in a class action lawsuit. The suit alleges that Sarepta misled investors regarding the safety of its ELEVIDYS drug, which is intended to treat Duchenne muscular dystrophy. ELEVIDYS has been linked to severe side effects, including patient deaths, which caused the company to halt recruitment and dosing in clinical trials. As a result, Sarepta's stock price plummeted, with significant drops on March 18, 2025, June 15, 2025, and June 24, 2025.

Key Takeaways:

  • Sarepta Therapeutics, Inc. faces a class action lawsuit alleging that the company misled investors about the safety of its ELEVIDYS drug.
  • ELEVIDYS, a prescription gene therapy, is intended for patients with Duchenne muscular dystrophy.
  • During the class period, defendants allegedly failed to disclose significant safety risks associated with ELEVIDYS, including severe side effects and patient deaths.
  • Sarepta's stock price dropped significantly on three separate occasions due to the disclosure of adverse events and regulatory scrutiny.
  • The lead plaintiff must file a motion by August 25, 2025, to direct the litigation.
  • Shareholders who choose not to participate in the case can remain absent class members.
  • The law firm, Robbins LLP, is representing the plaintiff on a contingency fee basis, with no fees or expenses charged to shareholders.

Statistics:

  • Sarepta's stock price fell $27.81 per share, or 27.44%, to close at $73.54 on March 18, 2025.
  • Sarepta's stock price fell $15.24 per share, or 42.12%, to close at $20.91 on June 15, 2025.
  • Sarepta's stock price fell $1.52 per share, or 8.01%, to close at $17.46 on June 25, 2025.

Sources:

  • GLOBE NEWSWIRE (Aug. 18, 2025): SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) --
  • Robbins LLP (Aug. 18, 2025): The Allegations: Robbins LLP is Investigating Allegations that Sarepta Therapeutics, Inc. (SRPT) Mislead Investors Regarding the Safety its ELEVIDYS Drug
  • COMTEX_468134499 (Aug. 18, 2025): COMTEX_468134499/2010/2025-08-18T17:56:02

Read more